Orforglipron ATTAIN-1 Phase 3: 12.4% mean weight loss at 72 weeks on the top dose

Eli Lilly/Orforglipron (Foundayo)

In ATTAIN-1, Lilly's once-daily oral GLP-1 pill orforglipron (36 mg) produced 12.4% mean weight loss at 72 weeks versus 0.9% on placebo in 3,127 adults with obesity or overweight. The small-molecule pill requires no food restrictions and has a safety profile consistent with injectable GLP-1 drugs.

• Orforglipron 36 mg: 12.4% weight loss at 72 weeks versus 0.9% on placebo.
• 59.6% achieved at least 10% weight loss; 39.6% lost 15% or more.
• No food or water restrictions required; taken once daily.
• Safety and tolerability profile matched injectable GLP-1 therapies.